csbr-20211020

Date of report (Date of earliest event reported): October 20, 2021


Delaware	001-11504	52-1401755
(State or Other Jurisdiction	(Commission File Number)	(IRS Employer
of Incorporation)		Identification No.)

Registrant’s telephone number, including area code: (201) 808-8400

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


			¨			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


			¨			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


			¨			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


			¨			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of Each Class

Trading Symbol(s)

Name of Each Exchange on Which Registered

Common Stock, par value $0.001 per share

CSBR

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o


			Item 5.07.			Submission of Matters to a Vote of Security Holders.

On October 20, 2021, Champion’s Oncology, Inc. (the “Company”) held its Annual Meeting of the Stockholders (the “Annual Meeting”). The following matters were submitted to a vote of the stockholders at the Annual Meeting and the voting results were as follows, there being no broker non-votes for any matter:

1. Election of Directors. The seven director nominees named in the Company's 2021 proxy statement were elected to serve for a one-year term expiring at the 2022 Annual Meeting of the Stockholders or until their successors are duly elected and qualified, based upon the following votes:


Director Nominee	Votes For	Votes Withheld
Ronnie Morris, M.D.	7,933,533	729,586
Joel Ackerman	7,272,836	1,390,283
David Sidransky, M.D.	7,108,814	1,554,305
Daniel Mendelson	7,640,915	1,022,204
Robert Brainin	8,265,887	397,232
Scott R. Tobin	8,518,378	144,741
Philip Breitfeld, M.D.	7,742,805	920,314

2. Ratification of Appointment of Independent Registered Accounting Firm. The appointment of EisnerAmper LLP to serve as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2022, was ratified as follows:

3. Non-binding Advisory Resolution Relating to the Compensation of the Company’s Named Executive Officers. The proposal to approve, on a non-binding advisory basis, the compensation of the Company's named executive officers, as described in the Company's 2021 proxy statement, was approved by the following votes:

4. Approval of the 2021 Equity Incentive Plan. The proposal to approve the 2021 Equity Incentive Plan was approved by the following votes:

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	CHAMPIONS ONCOLOGY, INC.
	(Registrant)

Date: October 21, 2021	By:	/s/ David Miller
		David Miller
		Chief Financial Officer


Votes For	Votes Against	Abstain
8,762,596	326	19


Votes For	Votes Against	Abstain
8,531,715	103,135	28,269


Votes For	Votes Against	Abstain
7,451,194	1,211,189	736